BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lauenstein T, Ramirez-Garrido F, Kim YH, Rha SE, Ricke J, Phongkitkarun S, Boettcher J, Gupta RT, Korpraphong P, Tanomkiat W, Furtner J, Liu PS, Henry M, Endrikat J. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Invest Radiol 2015;50:416-22. [PMID: 25756684 DOI: 10.1097/RLI.0000000000000145] [Cited by in Crossref: 39] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Leisman S. Radiocontrast Toxicity. Adv Chronic Kidney Dis 2020;27:50-5. [PMID: 32147002 DOI: 10.1053/j.ackd.2019.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Cheong BYC, Wilson JM, Preventza OA, Muthupillai R. Gadolinium-Based Contrast Agents: Updates and Answers to Typical Questions Regarding Gadolinium Use. Tex Heart Inst J 2022;49:e217680. [PMID: 35612906 DOI: 10.14503/THIJ-21-7680] [Reference Citation Analysis]
3 Lunyera J, Mohottige D, Alexopoulos AS, Campbell H, Cameron CB, Sagalla N, Amrhein TJ, Crowley MJ, Dietch JR, Gordon AM, Kosinski AS, Cantrell S, Williams JW Jr, Gierisch JM, Ear B, Goldstein KM. Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review. Ann Intern Med 2020;173:110-9. [PMID: 32568573 DOI: 10.7326/M20-0299] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Splendiani A, Perri M, Marsecano C, Vellucci V, Michelini G, Barile A, Di Cesare E. Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients. Radiol Med 2018;123:125-34. [PMID: 28952018 DOI: 10.1007/s11547-017-0816-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
5 Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Med 2021;3:142-50. [PMID: 33604544 DOI: 10.1016/j.xkme.2020.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol CB, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018;5:2054358118778573. [PMID: 29977584 DOI: 10.1177/2054358118778573] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
7 Sattarova V, Gencturk M, Lee MS, McClelland CM. Gadoxetate Disodium-Enhanced Imaging of Gradenigo Syndrome in End-Stage Renal Disease. J Neuroophthalmol 2021;41:e375-7. [PMID: 33813531 DOI: 10.1097/WNO.0000000000001218] [Reference Citation Analysis]
8 Tseng TY, Tseng JH, Huang BS, Lin SY, Chen CB, Fang YW, Lin G, Lai YC. Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging. Abdom Radiol (NY) 2021;46:3995-4001. [PMID: 33742216 DOI: 10.1007/s00261-021-03045-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hama Y, Tate E. Superparamagnetic iron oxide-enhanced MRI-guided stereotactic ablative radiation therapy for liver metastasis. Rep Pract Oncol Radiother 2021;26:470-4. [PMID: 34277103 DOI: 10.5603/RPOR.a2021.0052] [Reference Citation Analysis]
10 Starmans LWE, Hummelink MAPM, Rossin R, Kneepkens ECM, Lamerichs R, Donato K, Nicolay K, Grüll H. 89 Zr- and Fe-Labeled Polymeric Micelles for Dual Modality PET and T1 -Weighted MR Imaging. Adv Healthc Mater 2015;4:2137-45. [PMID: 26333024 DOI: 10.1002/adhm.201500414] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
11 Endrikat J, Dohanish S, Schleyer N, Schwenke S, Agarwal S, Balzer T. 10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016. Invest Radiol 2018;53:541-50. [PMID: 29547493 DOI: 10.1097/RLI.0000000000000462] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 7.7] [Reference Citation Analysis]
12 Michaely HJ, Aschauer M, Deutschmann H, Bongartz G, Gutberlet M, Woitek R, Ertl-Wagner B, Kucharczyk W, Hammerstingl R, De Cobelli F, Rosenberg M, Balzer T, Endrikat J. Gadobutrol in Renally Impaired Patients: Results of the GRIP Study. Invest Radiol 2017;52:55-60. [PMID: 27529464 DOI: 10.1097/RLI.0000000000000307] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 5.2] [Reference Citation Analysis]
13 Paro EDL, Puchnick A, Szejnfeld J, Goldman SM. Use of diffusion-weighted imaging in the noninvasive diagnostic of obstructed biliary ducts. Abdom Radiol (NY) 2021;46:268-79. [PMID: 32666232 DOI: 10.1007/s00261-020-02636-x] [Reference Citation Analysis]
14 Young LK, Matthew SZ, Houston JG. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals. Eur Radiol 2019;29:1922-30. [PMID: 30276674 DOI: 10.1007/s00330-018-5737-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
15 Zech CJ, Schwenke C, Endrikat J. Diagnostic Efficacy and Safety of Gadoxetate Disodium vs Gadobenate Dimeglumine in Patients With Known or Suspected Focal Liver Lesions: Results of a Clinical Phase III Study. Magn Reson Insights 2019;12:1178623X19827976. [PMID: 30799932 DOI: 10.1177/1178623X19827976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]